Adjuvant treatment with dabrafenib plus trametinib prolongs relapse-free survival (RFS) in patients with resected stage III BRAF V600-mutant melanoma, according to a 5-year analysis of the COMBI-AD* study presented at the ASCO20 Virtual Scientific Program.
The investigational, highly selective MET inhibitor savolitinib demonstrated encouraging efficacy and safety vs standard-of-care sunitinib in patients with MET-driven*, unresectable and locally advanced, or metastatic papillary renal cell carcinoma (PRCC), according to the phase III SAVOIR trial results presented at ASCO 2020.
Pembrolizumab as first-line therapy significantly improves progression-free survival (PFS) vs chemotherapy in patients with microsatellite instability-high (MSI-H)/mismatch-repair deficient (dMMR) metastatic colorectal cancer (mCRC), according to results of the KEYNOTE-177 study reported at the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Programme.
Osimertinib as adjuvant therapy following complete resection of early-stage EGFR-positive non-small-cell lung cancer (NSCLC) has demonstrated superior disease-free survival (DFS) benefit vs placebo that led to early unblinding of the ADAURA study, according to results reported at the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Programme.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.